Defence Therapeutics Inc.
DTCFF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $14 | $0 | $0 |
| Gross Profit | $0 | -$14 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,861 | $3,581 | $3,760 | $1,159 |
| G&A Expenses | $1,248 | $641 | $1,036 | $1,360 |
| SG&A Expenses | $8,794 | $2,899 | $3,560 | $1,701 |
| Sales & Mktg Exp. | $1,710 | $1,963 | $2,524 | $341 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,656 | $6,481 | $7,320 | $2,859 |
| Operating Income | -$12,656 | -$6,481 | -$7,296 | -$2,859 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$537 | -$387 | -$70 | $0 |
| Pre-Tax Income | -$13,193 | -$6,868 | -$7,344 | -$2,859 |
| Tax Expense | $0 | -$105 | $0 | $0 |
| Net Income | -$13,193 | -$6,763 | -$7,344 | -$2,859 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.17 | -0.2 | -0.11 |
| % Growth | -76.5% | 15% | -81.8% | – |
| EPS Diluted | -0.3 | -0.17 | -0.2 | -0.11 |
| Weighted Avg Shares Out | 44,632 | 39,660 | 36,077 | 26,596 |
| Weighted Avg Shares Out Dil | 44,632 | 39,660 | 36,077 | 26,596 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7 | $0 | $0 |
| Interest Expense | $0 | $263 | $0 | $0 |
| Depreciation & Amortization | $71 | $14 | $7,274 | $2,826 |
| EBITDA | -$12,676 | -$6,481 | $0 | $0 |
| % Margin | – | – | – | – |